Beam Therapeutics [BEAM] vs Vertex [VRTX] Detailed Stock Comparison

Beam Therapeutics Inc.

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Beam Therapeutics Inc. wins in 3 metrics, Vertex Pharmaceuticals Inc. wins in 15 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Beam Therapeutics Inc. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) -37.23 28.40 Vertex Pharmaceuticals Inc.
Price-to-Book Ratio 2.46 5.92 Beam Therapeutics Inc.
Debt-to-Equity Ratio 12.45 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio 0.12 0.88 Beam Therapeutics Inc.
EV/EBITDA -5.42 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) -57.24% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) -15.29% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -8.11% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -18.55% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-360.05M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 108.02% 1.24% Beam Therapeutics Inc.
Price-to-Sales Ratio (TTM) 22.56 9.22 Vertex Pharmaceuticals Inc.
Enterprise Value $1.96B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 14.00 8.83 Vertex Pharmaceuticals Inc.
Gross Profit Margin (TTM) N/A 85.39% N/A
Revenue per Share (TTM) $1 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-0.81 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 2.19 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 25.75% 1.78% Vertex Pharmaceuticals Inc.

Beam Therapeutics Inc. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

BEAM
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Beam Therapeutics Inc.2.04%-7.34%-1.76%8.56%10.51%8.88%
Vertex Pharmaceuticals Inc.0.76%-2.03%-0.35%-9.68%-7.51%-5.26%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Beam Therapeutics Inc.108.02%-3.23%-60.14%59.70%59.70%59.70%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: Beam Therapeutics Inc. vs Vertex Pharmaceuticals Inc.

MetricBEAMVRTX
Market Information
Market Cap i$3.10B$109.45B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i1,991,5771,057,061
90 Day Avg. Volume i2,031,6421,272,097
Last Close$29.55$428.34
52 Week Range$15.60 - $36.44$362.50 - $507.92
% from 52W High-18.91%-15.67%
All-Time High$138.52 (Jun 28, 2021)$519.88 (Nov 04, 2024)
% from All-Time High-78.67%-17.61%
Growth Metrics
Quarterly Revenue Growth2.80%0.10%
Quarterly Earnings Growth2.80%0.31%
Financial Health
Profit Margin (TTM) i-0.57%0.33%
Operating Margin (TTM) i-0.15%0.40%
Return on Equity (TTM) i-0.08%0.23%
Debt to Equity (MRQ) i12.4510.91
Cash & Liquidity
Book Value per Share (MRQ)$12.48$73.49
Cash per Share (MRQ)$12.54$26.01
Operating Cash Flow (TTM) i$-345,102,016$3.63B
Levered Free Cash Flow (TTM) i$-220,311,120$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Beam Therapeutics Inc. vs Vertex Pharmaceuticals Inc.

MetricBEAM (Apr 24, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-37.2328.40
Forward P/E i-6.9919.95
PEG Ratio i0.120.88
Price to Sales (TTM) i22.569.22
Price to Book (MRQ) i2.465.92
Market Capitalization
Market Capitalization i$3.10B$109.45B
Enterprise Value i$1.96B$105.96B
Enterprise Value Metrics
Enterprise to Revenue i14.008.83
Enterprise to EBITDA i-5.4221.78
Risk & Other Metrics
Beta i2.190.37
Book Value per Share (MRQ) i$12.48$73.49

Financial Statements Comparison: Beam Therapeutics Inc. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBEAM (2025)VRTX (2025)
Revenue/Sales i139.74M12.00B
Cost of Goods Sold iN/A1.65B
COGS % of Revenue i0.0%13.8%
Gross Profit iN/A10.35B
Gross Margin i0.0%86.2%
Research & Development i409.62M4.04B
Operating Income (EBIT) i-383.69M4.55B
Operating Margin i-274.6%37.9%
EBITDA i-366.22M5.25B
EBITDA Margin i-262.1%43.7%
Pre-Tax Income i-79.99M4.64B
Pre-Tax Income % of Revenue i-57.2%38.7%
Income Tax i0690.00M
Income Tax % of Revenue i0.0%5.7%
Net Income (Profit) i-79.99M3.95B
Profit Margin i-57.2%32.9%

Balance Sheet & Liquidity Metrics

MetricBEAM (2025)VRTX (2025)
Cash & Equivalents i294.94M5.08B
Total Current Assets i1.27B11.20B
Total Current Assets % of Revenue i907.9%93.3%
Total Current Liabilities i96.94M3.86B
Total Current Liabilities % of Revenue i69.4%32.2%
Long-Term Debt i139.76M1.95B
Long-Term Debt % of Revenue i100.0%16.3%
Total Shareholders Equity i1.24B18.67B
Retained Earnings i-1.64B13.56B
Retained Earnings % of Revenue i-1,174.5%113.0%
Property, Plant & Equipment i177.72M1.56B

Cash Flow Statement Comparison

MetricBEAM (2025)VRTX (2025)
Operating Cash Flow i-81.95M3.77B
Operating Cash Flow % of Revenue i-58.6%31.4%
Capital Expenditures i-14.95M-437.60M
Free Cash Flow i-360.05M3.19B
FCF Margin i-257.7%26.6%
Debt Repayment i0-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricBEAMVRTX
Shares Short i23.36M4.02M
Short Ratio i10.872.80
Short % of Float i25.75%1.78%
Shares Outstanding i101.75M253.99M
Float Shares i87.79M253.24M
% Held by Insiders i1.36%0.21%
% Held by Institutions i103.68%97.60%
% Held by Public i-5.04%2.19%

Dividend Analysis & Yield Comparison: Beam Therapeutics Inc. vs Vertex Pharmaceuticals Inc.

MetricBEAMVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A